220 related articles for article (PubMed ID: 20388792)
1. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.
Nadiminty N; Lou W; Sun M; Chen J; Yue J; Kung HJ; Evans CP; Zhou Q; Gao AC
Cancer Res; 2010 Apr; 70(8):3309-19. PubMed ID: 20388792
[TBL] [Abstract][Full Text] [Related]
2. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.
Nadiminty N; Tummala R; Liu C; Yang J; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2013 Aug; 12(8):1629-37. PubMed ID: 23699654
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation.
Nadiminty N; Chun JY; Lou W; Lin X; Gao AC
Prostate; 2008 Dec; 68(16):1725-33. PubMed ID: 18781579
[TBL] [Abstract][Full Text] [Related]
4. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells.
Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW
Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080
[TBL] [Abstract][Full Text] [Related]
5. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
[TBL] [Abstract][Full Text] [Related]
6. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81).
Mehraein-Ghomi F; Church DR; Schreiber CL; Weichmann AM; Basu HS; Wilding G
Genes Cancer; 2015 Sep; 6(9-10):428-44. PubMed ID: 26622945
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells.
Cui Y; Nadiminty N; Liu C; Lou W; Schwartz CT; Gao AC
Endocr Relat Cancer; 2014 Jun; 21(3):435-42. PubMed ID: 24659479
[TBL] [Abstract][Full Text] [Related]
9. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.
Jin RJ; Lho Y; Connelly L; Wang Y; Yu X; Saint Jean L; Case TC; Ellwood-Yen K; Sawyers CL; Bhowmick NA; Blackwell TS; Yull FE; Matusik RJ
Cancer Res; 2008 Aug; 68(16):6762-9. PubMed ID: 18701501
[TBL] [Abstract][Full Text] [Related]
10. NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells.
Lessard L; Saad F; Le Page C; Diallo JS; Péant B; Delvoye N; Mes-Masson AM
Cell Signal; 2007 May; 19(5):1093-100. PubMed ID: 17292587
[TBL] [Abstract][Full Text] [Related]
11. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
Ko S; Shi L; Kim S; Song CS; Chatterjee B
Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
[TBL] [Abstract][Full Text] [Related]
12. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.
Nadiminty N; Dutt S; Tepper C; Gao AC
Prostate; 2010 Feb; 70(3):276-87. PubMed ID: 19827050
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine-317 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells.
Lee MS; Igawa T; Lin MF
Oncogene; 2004 Apr; 23(17):3048-58. PubMed ID: 14990987
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
16. ARF represses androgen receptor transactivation in prostate cancer.
Lu W; Xie Y; Ma Y; Matusik RJ; Chen Z
Mol Endocrinol; 2013 Apr; 27(4):635-48. PubMed ID: 23449888
[TBL] [Abstract][Full Text] [Related]
17. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
Li N; Chen M; Truong S; Yan C; Buttyan R
Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
[TBL] [Abstract][Full Text] [Related]
18. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
19. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.
Kasina S; Macoska JA
Mol Cell Endocrinol; 2012 Apr; 351(2):249-63. PubMed ID: 22245379
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
